Upper Respiratory Tract Infection (URTI) Respiratory Upper respiratory tract infection (URTI)
Conditions
Interventions
Patients in the intervention group take loxoprofen sodium (60 mg/tablet) and those in the control group take a placebo similar to active loxoprofen
Sponsors
Kyoto University (Japan)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients aged 18 through to 65 years who exhibit symptoms or signs in both the nose and pharynx and have visited physicians within 48 hours after symptom onset
Exclusion criteria
Exclusion criteria: 1. Patients who were clinically supposed to suffer from influenza, pneumonia of any cause, ß-streptococcus tonsillitis, and other bacterial infections 2. Patients with serious or confusing underlying diseases including: bronchial asthma, peptic ulcer, diabetes mellitus, and allergic rhinitis 3. Immunocompromized or pregnant persons 4. Patients who were currently using antibiotics, systemic corticosteroids, immunosuppressants or anticoagulants 5. Patients who had taken NSAIDs or Chinese herbal medicines as cold remedies within 12 hours
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The interval, in days, from the onset of any URTI symptom to the disappearance of all URTI symptoms | — |
Secondary
| Measure | Time frame |
|---|---|
| Severity of the URTI symptoms | — |
Countries
Japan
Outcome results
None listed